Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCS-499
- Development stage
- Phase 2
- Lead developer
- Processa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PCS-499 is a small molecule, orally administered drug that is a deuterated analog of one of the major metabolites of pentoxifylline. It was originally developed by Concert Pharmaceuticals and later acquired by Sun Pharmaceutical Industries. PCS-499 and its metabolites affect multiple biological pathways, including anti-inflammatory, antifibrotic, and antioxidant mechanisms. Its primary mechanism involves inhibition of phosphodiesterases (PDEs), which may contribute to its therapeutic effects in conditions characterized by inflammation and tissue degeneration. The drug has been investigated for necrobiosis lipoidica (NL), a rare skin disorder with no currently approved FDA treatments, as well as for diabetic nephropathy and chronic kidney disease.
- Other names
- CTP-499CTP499CTP 499deuterated s-lisofyllineFLV771E8ZVFLV-771E8ZVFLV 771E8ZV
02
Targets
PDE6 (Phosphodiesterase 6)
Beyond the preview
Go deeper on PCS-499.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCS-499.